RETT SYNDROME RESEARCH TRUST
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2008-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://reverserett.org/
Clinical Trials
5
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Validating Innovative Biosensors for Rett Autonomic Symptom Tracking
- Conditions
- Rett Syndrome
- First Posted Date
- 2024-03-29
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Rett Syndrome Research Trust
- Target Recruit Count
- 30
- Registration Number
- NCT06338267
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
Development of the ORCA Communication Measure for Rett Syndrome
- Conditions
- Rett Syndrome
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2022-04-22
- Lead Sponsor
- Rett Syndrome Research Trust
- Target Recruit Count
- 272
- Registration Number
- NCT04920110
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
The Rett Syndrome Global Registry
- Conditions
- Rett Syndrome
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Rett Syndrome Research Trust
- Target Recruit Count
- 5000
- Registration Number
- NCT04900493
- Locations
- 🇺🇸
Rett Syndrome Research Trust, Trumbull, Connecticut, United States
ASSESSING EMERALD AND MC10 BIOSTAMP nPOINT BIOSENSORS FOR RETT SYNDROME
- Conditions
- Rett Syndrome
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Rett Syndrome Research Trust
- Target Recruit Count
- 21
- Registration Number
- NCT04514549
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
A Study to Evaluate Ketamine for the Treatment of Rett Syndrome
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Rett Syndrome Research Trust
- Target Recruit Count
- 23
- Registration Number
- NCT03633058
- Locations
- 🇺🇸
University of Alabama Birmingham School of Medicine, Birmingham, Alabama, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
News
Apertura Gene Therapy Partners with Rett Syndrome Research Trust to Advance Blood-Brain Barrier-Crossing Gene Therapy Platform
Apertura Gene Therapy and Rett Syndrome Research Trust announced a collaboration to license Apertura's TfR1-targeted AAV capsid technology for developing genetic medicines to treat Rett syndrome.
ProQR Advances RNA Editing Pipeline with Four Clinical Readouts Expected by 2026
ProQR Therapeutics is advancing its Axiomer™ RNA editing platform across liver and CNS programs, with its lead program AX-0810 for cholestatic diseases on track for CTA filing in Q2 2025.